{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:30:04Z","timestamp":1786714204298,"version":"build-2736575974"},"reference-count":41,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypertriglyceridaemia is a major risk factor and rising aetiology for acute pancreatitis (AP), a condition associated with significant morbidity and mortality. Novel triglyceride-lowering therapies targeting key regulators of lipoprotein metabolism, specifically apolipoprotein C-III (APOC3), angiopoietin-like 3 protein (ANGPTL3) and angiopoietin-like 4 protein (ANGPTL4), have shown promise in reducing triglyceride levels. This study aims to evaluate the efficacy and safety of APOC3, ANGPTL3 and ANGPTL4 inhibitors for reducing the episodes of AP in patients with hypertriglyceridaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic search of PubMed (National Library of Medicine), Web of Science (Clarivate), Embase (Ovid) and the Cochrane Library (Wiley) will be conducted to identify randomised controlled trials published from inception to May 2026. Eligible studies will include adults with hypertriglyceridaemia (fasting triglyceride level \u2265500 mg\/dL (5.6 mmol\/L)), comparing APOC3, ANGPTL3 or ANGPTL4 inhibitors against placebo. The primary outcome will be the incidence of AP. Secondary outcomes include the per cent change in lipid parameters (triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol) and safety profiles. Two reviewers will independently conduct study selection, data extraction and risk of bias assessment. Meta-analysis will be performed using R software, with effects expressed as risk ratio for dichotomous outcomes and mean differences for continuous outcomes. Heterogeneity, subgroup analyses, sensitivity analyses and publication bias will be assessed. The certainty of evidence will be evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical review is not required as this study involves no human participants and relies on previously published data. The findings will be disseminated through peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251174198.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-120485","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:40:24Z","timestamp":1786711224000},"page":"e120485","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Novel triglyceride-lowering therapies to reduce the risk of acute pancreatitis in hypertriglyceridaemia: a protocol for systematic review and meta-analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Yongzi","family":"Wu","sequence":"first","affiliation":[{"name":"West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China\u2013Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China\u2013Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Luo","sequence":"additional","affiliation":[{"name":"West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China\u2013Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Jiangxi Medical College, Nanchang University, Nanchang, China"},{"name":"Pancreatic Disease Research Institute, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Jiangxi Medical College, Nanchang University, Nanchang, China"},{"name":"Pancreatic Disease Research Institute, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Windsor","sequence":"additional","affiliation":[{"name":"Surgical and Translational Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-562X","authenticated-orcid":false,"given":"Robert","family":"Sutton","sequence":"additional","affiliation":[{"name":"Trauma and Emergency General Surgery Service, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Trauma and Emergency General Surgery Service, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"},{"name":"Liverpool Pancreatitis Research Group, Institute of Systems, Molecular and Integrative Biology, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Shi","sequence":"additional","affiliation":[{"name":"West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China\u2013Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China\u2013Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China"},{"name":"West China Biobank, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081405401482000_16.8.e120485.1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.pan.2025.04.020","article-title":"International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society","volume":"25","author":"P\u00e1rniczky","year":"2025","journal-title":"Pancreatology"},{"key":"2026081405401482000_16.8.e120485.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74943-8","article-title":"Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis","volume":"10","author":"B\u00e1lint","year":"2020","journal-title":"Sci Rep"},{"key":"2026081405401482000_16.8.e120485.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3109","article-title":"Management of hypertriglyceridemia","volume":"371","author":"Simha","year":"2020","journal-title":"BMJ"},{"key":"2026081405401482000_16.8.e120485.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-025-03954-4","article-title":"A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026081405401482000_16.8.e120485.5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"173","author":"Murphy","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026081405401482000_16.8.e120485.6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026081405401482000_16.8.e120485.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01525-5","article-title":"Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study","volume":"21","author":"Patel","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026081405401482000_16.8.e120485.8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.14309\/ajg.0000000000002198","article-title":"High Triglyceride Variability Increases the Risk of First Attack of Acute Pancreatitis","volume":"118","author":"Tung","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026081405401482000_16.8.e120485.9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.hpb.2019.01.015","article-title":"Hypertriglyceridaemia-associated acute pancreatitis: diagnosis and impact on severity","volume":"21","author":"Zhang","year":"2019","journal-title":"HPB (Oxford)"},{"key":"2026081405401482000_16.8.e120485.10","doi-asserted-by":"crossref","first-page":"108544","DOI":"10.1016\/j.pharmthera.2023.108544","article-title":"Severe hypertriglyceridemia: Existing and emerging therapies","volume":"251","author":"Malick","year":"2023","journal-title":"Pharmacol Ther"},{"key":"2026081405401482000_16.8.e120485.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32337-x","article-title":"The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis","volume":"8","author":"Kiss","year":"2018","journal-title":"Sci Rep"},{"key":"2026081405401482000_16.8.e120485.12","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.14309\/ajg.0000000000003319","article-title":"Clinical Outcomes in a Multicenter Cohort Involving 919 Patients With Hypertriglyceridemia-Associated Acute Pancreatitis","volume":"120","author":"Deng","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026081405401482000_16.8.e120485.13","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s11427-024-2900-6","article-title":"Global burden and characterization of hypertriglyceridemia-induced acute pancreatitis: results from a systematic review and a multi-center cohort study","volume":"68","author":"Fan","year":"2025","journal-title":"Sci China Life Sci"},{"key":"2026081405401482000_16.8.e120485.14","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cgh.2020.08.016","article-title":"Genetic Variants Associated With Increased Plasma Levels of Triglycerides, via Effects on the Lipoprotein Lipase Pathway, Increase Risk of Acute Pancreatitis","volume":"19","author":"Hansen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026081405401482000_16.8.e120485.15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/hvad094","article-title":"Hypertriglyceridemia-Associated Pancreatitis: New Concepts and Potential Mechanisms","volume":"69","author":"Hansen","year":"2023","journal-title":"Clin Chem"},{"key":"2026081405401482000_16.8.e120485.16","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13916","article-title":"Mechanisms linking hypertriglyceridemia to acute pancreatitis","volume":"237","author":"Kiss","year":"2023","journal-title":"Acta Physiol (Oxf)"},{"key":"2026081405401482000_16.8.e120485.17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026081405401482000_16.8.e120485.18","unstructured":"Feingold KR . Triglyceride lowering drugs. In: Feingold KR , Adler RA , Ahmed SF , et al , eds. Endotext. South Dartmouth (MA): MDText.com, Inc, 2000."},{"key":"2026081405401482000_16.8.e120485.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000709"},{"key":"2026081405401482000_16.8.e120485.20","doi-asserted-by":"crossref","DOI":"10.3390\/ph18020147","article-title":"Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review","volume":"18","author":"Zimodro","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081405401482000_16.8.e120485.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101352","article-title":"Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide","volume":"24","author":"Bajaj","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026081405401482000_16.8.e120485.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00676-y"},{"key":"2026081405401482000_16.8.e120485.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.11.005"},{"key":"2026081405401482000_16.8.e120485.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308027"},{"key":"2026081405401482000_16.8.e120485.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510926"},{"key":"2026081405401482000_16.8.e120485.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612790"},{"key":"2026081405401482000_16.8.e120485.27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jacl.2023.08.003","article-title":"Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants","volume":"17","author":"Perera","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026081405401482000_16.8.e120485.28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target Populations for Novel Triglyceride-Lowering Therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081405401482000_16.8.e120485.29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.eprac.2024.08.013","article-title":"Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis","volume":"30","author":"Kamrul-Hasan","year":"2024","journal-title":"Endocr Pract"},{"key":"2026081405401482000_16.8.e120485.30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s11154-024-09893-x","article-title":"Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis","volume":"25","author":"Masson","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"2026081405401482000_16.8.e120485.31","doi-asserted-by":"crossref","first-page":"156187","DOI":"10.1016\/j.metabol.2025.156187","article-title":"Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials","volume":"167","author":"de Moura de Souza","year":"2025","journal-title":"Metabolism"},{"key":"2026081405401482000_16.8.e120485.32","article-title":"Efficacy and Safety of Olezarsen in Dyslipidemia: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials","volume":"37","author":"Tristan","year":"2025","journal-title":"J Saudi Heart Assoc"},{"key":"2026081405401482000_16.8.e120485.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512761"},{"key":"2026081405401482000_16.8.e120485.34","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026081405401482000_16.8.e120485.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026081405401482000_16.8.e120485.36","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20f13681","article-title":"Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2026081405401482000_16.8.e120485.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2026081405401482000_16.8.e120485.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2026081405401482000_16.8.e120485.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2026081405401482000_16.8.e120485.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d7762","article-title":"Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey","volume":"344","author":"Ahmed","year":"2012","journal-title":"BMJ"},{"key":"2026081405401482000_16.8.e120485.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:40:29Z","timestamp":1786711229000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-120485"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120485","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}